<p>在过去的 7 天里，美国市场上涨了 3.1%，过去一年累计上涨了 27%，预计年收益增长为 16%。在如此强劲的市场环境中，拥有高内部持股的成长型公司尤其具有吸引力，因为这通常表明那些与业务运营和未来前景最接近的人士对公司的强烈信心。</p>
<h3>美国高内部持股的十大成长型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>优信 (UXIN)</td>
<td>35.6%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>13%</td>
<td>52.6%</td>
</tr>
<tr>
<td>Precigen (PGEN)</td>
<td>11.9%</td>
<td>68.4%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17%</td>
<td>53.2%</td>
</tr>
<tr>
<td>GBank Financial Holdings (GBFH)</td>
<td>27.3%</td>
<td>42.2%</td>
</tr>
<tr>
<td>Enovix (ENVX)</td>
<td>11.4%</td>
<td>41.1%</td>
</tr>
<tr>
<td>Clene (CLNN)</td>
<td>13.2%</td>
<td>62.2%</td>
</tr>
<tr>
<td>Better Home &amp; Finance Holding (BETR)</td>
<td>20.7%</td>
<td>97.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.3%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.3%</td>
<td>21.6%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们筛选出的 203 只高内部持股的快速成长美国公司的完整名单。</p>
<p>让我们探索筛选结果中的几个突出选项。</p>
<h2>ASP Isotopes (ASPI)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> ASP Isotopes Inc. 是一家处于开发阶段的先进材料公司，专注于生产、分销、营销和销售同位素，市值为 5.6405 亿美元。</p>
<p><strong>运营：</strong> 该公司主要通过两个部门产生收入：建筑服务，收入为 1818 万美元，以及专业同位素及相关服务，贡献 567 万美元。</p>
<p><strong>内部持股：</strong> 13.5%</p>
<p><strong>收入增长预测：</strong> 年增长 49.4%。</p>
<p>ASP Isotopes 正在经历显著的收入增长，预计年增长率为 49.4%，超过美国市场平均水平。尽管过去经历了股东稀释和股价波动，该公司预计将在三年内实现盈利。最近的进展包括其 Renergen 氦气项目的进展和核燃料生产的战略合作伙伴关系。然而，仍面临延迟提交 SEC 文件和预计 2025 年净亏损 1.7509 亿美元（收入 2385 万美元）的重大挑战。</p>
<ul>
<li>在我们的收益增长报告中更详细地了解 ASP Isotopes 的潜力。</li>
<li>我们的 ASP Isotopes 估值报告分析表明，其股价可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8686b2df-74f7-4596-899d-4091f07eee9a/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8686b2df-74f7-4596-899d-4091f07eee9a/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 4 月的 ASPI 收益和收入增长</p>
<h2>Eton Pharmaceuticals (ETON)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Eton Pharmaceuticals, Inc. 是一家制药公司，开发和商业化罕见疾病的治疗方案，市值为 7.1922 亿美元。</p>
<p><strong>运营：</strong> 该公司的收入主要来自其专注于开发和商业化处方药产品的部门，收入为 7995 万美元。</p>
<p><strong>内部持股：</strong> 15%</p>
<p><strong>收入增长预测：</strong> 年增长 29.8%。</p>
<p>Eton Pharmaceuticals 预计将实现显著增长，收入预计年增长 29.8%，超过美国市场平均水平。最近获得 FDA 对 DESMODA 的批准以及收购 HEMANGEOL 商业化权利增强了其产品组合。该公司预计 2026 年收入将超过 1.1 亿美元，得益于战略性许可交易和对超罕见疾病的关注。尽管 2025 年净亏损 460 万美元，Eton 计划在三年内实现盈利。</p>
<ul>
<li>在这里通过我们的全面分析师估计报告深入了解 Eton Pharmaceuticals 的复杂性。</li>
<li>我们的估值报告揭示了 Eton Pharmaceuticals 的股票可能以溢价交易的可能性。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/138d2dd4-ea25-478d-b12d-9bef35fe2f81/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/138d2dd4-ea25-478d-b12d-9bef35fe2f81/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 4 月的 ETON 收益和收入增长</p>
<h2>FirstSun Capital Bancorp (FSUN)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> FirstSun Capital Bancorp 是 Sunflower Bank, National Association 的银行控股公司，市值为 10.5 亿美元，为美国中小型企业提供商业和消费者银行及金融服务。</p>
<p><strong>运营：</strong> 该公司的收入主要来自其银行部门，收入为 3.226 亿美元，另有 7656 万美元来自抵押贷款业务，而公司部门则反映出 449 万美元的亏损。</p>
<p><strong>内部持股：</strong> 37.1%</p>
<p><strong>收入增长预测：</strong> 年增长 31.9%。</p>
<p>FirstSun Capital Bancorp 正在经历强劲增长，预计收益年增长 43.6%，超过美国市场平均水平。该公司以显著折扣交易于其估计的公允价值，并相较于同行提供良好的相对价值。最近的董事会变动包括从 First Foundation Inc. 增加关键董事，以增强合并后的治理。尽管被多个指数剔除，FirstSun 的内部购买仍然积极，表明对其增长轨迹的信心。</p>
<ul>
<li>在这里深入了解 FirstSun Capital Bancorp 的全面分析未来增长报告。</li>
<li>我们的估值报告揭示了 FirstSun Capital Bancorp 的股票可能以折扣交易的可能性。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1348cc44-c00a-4259-bc99-9e48d6623403/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1348cc44-c00a-4259-bc99-9e48d6623403/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 4 月的 FSUN 收益和收入增长</p>
<h2>抓住机会</h2>
<ul>
<li>在这里深入了解我们识别的 203 只高内部持股的快速成长美国公司。</li>
<li>想要探索一些替代方案？我们发现 11 只预计明年将支付超过 6% 股息收益的美国股票。查看完整名单，免费获取。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不意图作为财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>
<h3><strong>新功能：</strong> 在一个地方管理您的所有股票投资组合</h3>
<p>我们为股票投资者创建了 <strong>终极投资组合伴侣</strong>，<strong>而且是免费的。</strong></p>
<p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
<p>• 通过电子邮件或手机接收新的警告信号或风险提示</p>
<p>• 跟踪您股票的公允价值</p>
<p>免费试用演示投资组合</p>

优信

ETON

FSUN

<p>美国市场在过去一周上涨了 3.1%，在过去一年中上涨了 27%，预计年收益增长将达到 16%。高内部持股的成长型公司被认为是有吸引力的投资。顶尖公司包括优信（内部持股 35.6%，收益增长 74.1%）和 Eton Pharmaceuticals（内部持股 15%，收益增长 29.8%）。ASP Isotopes 和 FirstSun Capital Bancorp 也显示出强劲的增长潜力。文章强调了内部持股作为信心指标的重要性，并提供了对各公司财务预测和市场地位的见解</p>

<p>Over the last 7 days, the United States market has risen by 3.1%, contributing to a substantial 27% climb over the past year, with earnings forecasted to grow by 16% annually. In such a robust market environment, growth companies with high insider ownership can be particularly attractive as they often indicate strong confidence from those closest to the business operations and future prospects.</p>
<div class="lb-trans"><p>在过去的 7 天里，美国市场上涨了 3.1%，过去一年累计上涨了 27%，预计年收益增长为 16%。在如此强劲的市场环境中，拥有高内部持股的成长型公司尤其具有吸引力，因为这通常表明那些与业务运营和未来前景最接近的人士对公司的强烈信心。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In The United States</h3>
<div class="lb-trans"><h3>美国高内部持股的十大成长型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Uxin (UXIN)</td>
<td>35.6%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>13%</td>
<td>52.6%</td>
</tr>
<tr>
<td>Precigen (PGEN)</td>
<td>11.9%</td>
<td>68.4%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17%</td>
<td>53.2%</td>
</tr>
<tr>
<td>GBank Financial Holdings (GBFH)</td>
<td>27.3%</td>
<td>42.2%</td>
</tr>
<tr>
<td>Enovix (ENVX)</td>
<td>11.4%</td>
<td>41.1%</td>
</tr>
<tr>
<td>Clene (CLNN)</td>
<td>13.2%</td>
<td>62.2%</td>
</tr>
<tr>
<td>Better Home &amp; Finance Holding (BETR)</td>
<td>20.7%</td>
<td>97.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.3%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.3%</td>
<td>21.6%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>优信 (UXIN)</td>
<td>35.6%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>13%</td>
<td>52.6%</td>
</tr>
<tr>
<td>Precigen (PGEN)</td>
<td>11.9%</td>
<td>68.4%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17%</td>
<td>53.2%</td>
</tr>
<tr>
<td>GBank Financial Holdings (GBFH)</td>
<td>27.3%</td>
<td>42.2%</td>
</tr>
<tr>
<td>Enovix (ENVX)</td>
<td>11.4%</td>
<td>41.1%</td>
</tr>
<tr>
<td>Clene (CLNN)</td>
<td>13.2%</td>
<td>62.2%</td>
</tr>
<tr>
<td>Better Home &amp; Finance Holding (BETR)</td>
<td>20.7%</td>
<td>97.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.3%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.3%</td>
<td>21.6%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 203 stocks from our Fast Growing US Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>点击这里查看我们筛选出的 203 只高内部持股的快速成长美国公司的完整名单。</p>
</div><p>Let's explore several standout options from the results in the screener.</p>
<div class="lb-trans"><p>让我们探索筛选结果中的几个突出选项。</p>
</div><h2>ASP Isotopes (ASPI)</h2>
<div class="lb-trans"><h2>ASP Isotopes (ASPI)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> ASP Isotopes Inc. is a development stage advanced materials company focused on producing, distributing, marketing, and selling isotopes with a market cap of $564.05 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> ASP Isotopes Inc. 是一家处于开发阶段的先进材料公司，专注于生产、分销、营销和销售同位素，市值为 5.6405 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue from two main segments: Construction Services, which accounts for $18.18 million, and Specialist Isotopes and Related Services, contributing $5.67 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过两个部门产生收入：建筑服务，收入为 1818 万美元，以及专业同位素及相关服务，贡献 567 万美元。</p>
</div><p><strong>Insider Ownership:</strong> 13.5%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 13.5%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 49.4% p.a.</p>
<div class="lb-trans"><p><strong>收入增长预测：</strong> 年增长 49.4%。</p>
</div><p>ASP Isotopes is experiencing substantial revenue growth, with a forecast of 49.4% annually, surpassing the US market average. Despite past shareholder dilution and a volatile share price, the company is on track to become profitable in three years. Recent developments include advancements in its Renergen Helium Project and strategic partnerships for nuclear fuel production. However, challenges remain with delayed SEC filings and significant net losses reported for 2025 at US$175.09 million against revenues of US$23.85 million.</p>
<div class="lb-trans"><p>ASP Isotopes 正在经历显著的收入增长，预计年增长率为 49.4%，超过美国市场平均水平。尽管过去经历了股东稀释和股价波动，该公司预计将在三年内实现盈利。最近的进展包括其 Renergen 氦气项目的进展和核燃料生产的战略合作伙伴关系。然而，仍面临延迟提交 SEC 文件和预计 2025 年净亏损 1.7509 亿美元（收入 2385 万美元）的重大挑战。</p>
</div><ul>
<li>Take a closer look at ASP Isotopes' potential here in our earnings growth report.</li>
<li>The analysis detailed in our ASP Isotopes valuation report hints at an inflated share price compared to its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的收益增长报告中更详细地了解 ASP Isotopes 的潜力。</li>
<li>我们的 ASP Isotopes 估值报告分析表明，其股价可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8686b2df-74f7-4596-899d-4091f07eee9a/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/8686b2df-74f7-4596-899d-4091f07eee9a/chart/earnings-and-revenue-growth"/></p>
<p>ASPI Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 ASPI 收益和收入增长</p>
</div><h2>Eton Pharmaceuticals (ETON)</h2>
<div class="lb-trans"><h2>Eton Pharmaceuticals (ETON)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Eton Pharmaceuticals, Inc. is a pharmaceutical company that develops and commercializes treatments for rare diseases, with a market cap of $719.22 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Eton Pharmaceuticals, Inc. 是一家制药公司，开发和商业化罕见疾病的治疗方案，市值为 7.1922 亿美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its segment focused on developing and commercializing prescription drug products, which generated $79.95 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司的收入主要来自其专注于开发和商业化处方药产品的部门，收入为 7995 万美元。</p>
</div><p><strong>Insider Ownership:</strong> 15%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 15%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 29.8% p.a.</p>
<div class="lb-trans"><p><strong>收入增长预测：</strong> 年增长 29.8%。</p>
</div><p>Eton Pharmaceuticals is poised for significant growth, with revenue expected to increase by 29.8% annually, outpacing the US market average. Recent FDA approval of DESMODA and the acquisition of HEMANGEOL commercialization rights bolster its product portfolio. The company anticipates 2026 revenues exceeding US$110 million, supported by strategic in-licensing deals and a focus on ultra-rare diseases. Despite a net loss of US$4.6 million in 2025, Eton aims for profitability within three years.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals 预计将实现显著增长，收入预计年增长 29.8%，超过美国市场平均水平。最近获得 FDA 对 DESMODA 的批准以及收购 HEMANGEOL 商业化权利增强了其产品组合。该公司预计 2026 年收入将超过 1.1 亿美元，得益于战略性许可交易和对超罕见疾病的关注。尽管 2025 年净亏损 460 万美元，Eton 计划在三年内实现盈利。</p>
</div><ul>
<li>Navigate through the intricacies of Eton Pharmaceuticals with our comprehensive analyst estimates report here.</li>
<li>Our valuation report unveils the possibility Eton Pharmaceuticals' shares may be trading at a premium.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里通过我们的全面分析师估计报告深入了解 Eton Pharmaceuticals 的复杂性。</li>
<li>我们的估值报告揭示了 Eton Pharmaceuticals 的股票可能以溢价交易的可能性。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/138d2dd4-ea25-478d-b12d-9bef35fe2f81/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/138d2dd4-ea25-478d-b12d-9bef35fe2f81/chart/earnings-and-revenue-growth"/></p>
<p>ETON Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 ETON 收益和收入增长</p>
</div><h2>FirstSun Capital Bancorp (FSUN)</h2>
<div class="lb-trans"><h2>FirstSun Capital Bancorp (FSUN)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> FirstSun Capital Bancorp, with a market cap of $1.05 billion, operates as the bank holding company for Sunflower Bank, National Association, offering commercial and consumer banking and financial services to small and medium-sized companies in the United States.</p>
<div class="lb-trans"><p><strong>概述：</strong> FirstSun Capital Bancorp 是 Sunflower Bank, National Association 的银行控股公司，市值为 10.5 亿美元，为美国中小型企业提供商业和消费者银行及金融服务。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its Banking segment, which accounts for $322.60 million, supplemented by $76.56 million from Mortgage Operations, while the Corporate segment reflects a loss of $4.49 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司的收入主要来自其银行部门，收入为 3.226 亿美元，另有 7656 万美元来自抵押贷款业务，而公司部门则反映出 449 万美元的亏损。</p>
</div><p><strong>Insider Ownership:</strong> 37.1%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 37.1%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 31.9% p.a.</p>
<div class="lb-trans"><p><strong>收入增长预测：</strong> 年增长 31.9%。</p>
</div><p>FirstSun Capital Bancorp is experiencing robust growth, with earnings projected to rise 43.6% annually, surpassing the US market average. The company trades at a significant discount to its estimated fair value and offers good relative value compared to peers. Recent board changes include the addition of key directors from First Foundation Inc., enhancing governance post-merger. Despite being dropped from several indices, FirstSun's insider buying remains positive, indicating confidence in its growth trajectory.</p>
<div class="lb-trans"><p>FirstSun Capital Bancorp 正在经历强劲增长，预计收益年增长 43.6%，超过美国市场平均水平。该公司以显著折扣交易于其估计的公允价值，并相较于同行提供良好的相对价值。最近的董事会变动包括从 First Foundation Inc. 增加关键董事，以增强合并后的治理。尽管被多个指数剔除，FirstSun 的内部购买仍然积极，表明对其增长轨迹的信心。</p>
</div><ul>
<li>Delve into the full analysis future growth report here for a deeper understanding of FirstSun Capital Bancorp.</li>
<li>Our valuation report unveils the possibility FirstSun Capital Bancorp's shares may be trading at a discount.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里深入了解 FirstSun Capital Bancorp 的全面分析未来增长报告。</li>
<li>我们的估值报告揭示了 FirstSun Capital Bancorp 的股票可能以折扣交易的可能性。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1348cc44-c00a-4259-bc99-9e48d6623403/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/1348cc44-c00a-4259-bc99-9e48d6623403/chart/earnings-and-revenue-growth"/></p>
<p>FSUN Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 FSUN 收益和收入增长</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住机会</h2>
</div><ul>
<li>Dive into all 203 of the Fast Growing US Companies With High Insider Ownership we have identified here.</li>
<li>Want To Explore Some Alternatives? We've found 11 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里深入了解我们识别的 203 只高内部持股的快速成长美国公司。</li>
<li>想要探索一些替代方案？我们发现 11 只预计明年将支付超过 6% 股息收益的美国股票。查看完整名单，免费获取。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不意图作为财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一个地方管理您的所有股票投资组合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我们为股票投资者创建了 <strong>终极投资组合伴侣</strong>，<strong>而且是免费的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通过电子邮件或手机接收新的警告信号或风险提示</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟踪您股票的公允价值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免费试用演示投资组合</p>
</div>

2026 年 4 月内部持股比例高的顶级成长公司